English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -82.98%
Price change 2022 → 2023: -39.41%
Price change 2023 → 2024: -17.48%
Price change 2024 → 2025: -2.94%
Price change 2025 → 2026: -37.88%
Price change 2026 (year to date): -39.88%
Financial growth
Revenue CAGR (7 years): 1.94%
Earnings CAGR (7 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Negative or zero equity.
P/E (Price/Earnings)
P/E ratio: -0.71
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 40.58% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALAMA.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| AMA Corporation Plc | – | – | +1.9 % | 🔒 |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by AMA Corporation Plc over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 7.2 m | -8.4 m | -117.4 % | n/a |
| 2021 | 7.3 m | -11.0 m | -149.7 % | +2.2 % |
| 2022 | 4.8 m | -23.8 m | -499.2 % | -34.8 % |
| 2023 | 3.4 m | -9.0 m | -266.8 % | -29.7 % |
| 2024 | 2.8 m | -8.2 m | -295.0 % | -17.4 % |
| 2025 | 2.2 m | -6.3 m | -285.4 % | -20.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by AMA Corporation Plc over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 20.6 m | 8.6 m | 9.4 m | 5.8 m | 2.1 m |
| Total Debt | 4.7 m | 4.5 m | 4.0 m | 4.0 m | 2.8 m |
| Net Debt | -15.9 m | -4.1 m | -5.4 m | -1.8 m | 705,000 |
| Equity | 27.3 m | 5.7 m | 5.7 m | 2.5 m | -991,000 |
| Total assets | 38.2 m | 13.6 m | 12.8 m | 9.2 m | 4.4 m |
| Operating cash flow | -5.1 m | -10.5 m | -5.7 m | -6.3 m | -4.8 m |
| Investments (capex) | 5.2 m | 2.5 m | 55,000 | 106,000 | 41,000 |
| Free cash-flow | -10.3 m | -13.0 m | -5.8 m | -6.4 m | -4.8 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
AMA Corporation Plc compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| AMA Corporation Plc | 6.9 m | n/a | -285.4 % |
| Media Lab S.p.A. MLLAB.PA | 5.8 m | 36.7 | 11.0 % |
| TME Pharma N.V. ALTME.PA | 11.5 m | n/a | 0.0 % |
| Mauna Kea Technologies S.A. ALMKT.PA | 19.8 m | n/a | 131.0 % |
| Bluelinea S.A. ALBLU.PA | 1.9 m | n/a | -14.5 % |
| Plant Advanced Technologies S.A. ALPAT.PA | 5.1 m | 7.9 | 50.0 % |
| Biosynex S.A. ALBIO.PA | 17.1 m | n/a | -61.1 % |
| SpineGuard S.A. ALSGD.PA | 9.4 m | n/a | -55.0 % |
| Intrasense S.A. ALINS.PA | 12.1 m | n/a | -364.8 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in AMA Corporation Plc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Frequently asked questions about AMA Corporation Plc
What is the AMA Corporation Plc share price?
Latest recorded price: 0.115 EUR on 06/11/2026, for a market cap of 6.9 m USD.
What is the revenue of AMA Corporation Plc?
2.2 m USD for fiscal year 2025, with net income of -6.3 m USD (net margin -285.4 %).
How many employees does AMA Corporation Plc have?
40 full-time employees according to the latest published profile.
Who runs AMA Corporation Plc?
Etienne Guillemot is the company's chief executive.